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Abstract: Group B streptococcus (GBS) causes a high burden of neonatal and infant disease
globally. Implementing a vaccine for pregnant women is a promising strategy to prevent
neonatal and infant GBS disease and has been identified as a priority by the World Health
Organisation (WHO). GBS serotype-specific polysaccharide – protein conjugate vaccines are
at advanced stages of development, but a large number of participants would be required to
undertake Phase III clinical efficacy trials. Efforts are therefore currently focused on estab-
lishing serocorrelates of protection in natural immunity studies as an alternative pathway for
licensure of a GBS vaccine, followed by Phase IV studies to evaluate safety and effective-
ness. Protein vaccines are in earlier stages of development but are highly promising as they
might confer protection irrespective of serotype. Further epidemiological, immunological
and health economic studies are required to enable the vaccine to reach its target population
as soon as possible.
Keywords: Group B streptococcus, Streptococcus agalactiae, maternal vaccines, maternal
immunisation, neonatal sepsis, infant sepsis
Introduction
Group B streptococcus (GBS) is a leading cause of neonatal and infant sepsis and
meningitis globally.1–3 GBS can also cause stillbirths, prematurity and disease in
pregnant women, immunocompromised adults and the elderly but the highest
incidence of disease is in neonates and young infants.4
A systematic review and meta-analysis conducted in 2017 estimated a global
incidence of invasive infant GBS disease of 0.49 (95%Cl 0.43–0.56) per 1000 live
births.5 In 2015, GBS was estimated to have caused 319,000 cases of invasive
neonatal GBS disease globally, resulting in 90,000 deaths.3 Serotypes Ia, Ib, II, III
and V account for 98% of all rectovaginal colonisation in pregnant women
worldwide.6 The most frequent GBS serotype causing disease in infants is serotype
III (61.5%) followed by Ia (19.1%), V (6.7%) and Ib (5.7%).5 However, the
fulminating nature of disease during the first hours of life and the technical
difficulties in making an etiological diagnosis in many low- and middle-income
settings means that this might represent a significant underestimation of the true
GBS disease burden.7 Epidemiological data on the burden of GBS disease, espe-
cially from African countries, where most infant deaths from all-cause sepsis occur,
is urgently required.7 Infant mortality estimates are seven times higher in WHO
African region (51 per 1000 live births) compared to WHO European region (7 per
1000 live births).8
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Intrapartum Antibiotic Prophylaxis (IAP) has reduced
the incidence of early onset disease (EOD, occurring
from day 0 to 6 of life) in many countries using these
strategies, especially those that screen all pregnant women
for GBS rectovaginal colonisation during late pregnancy
and give IAP to all GBS-colonised women regardless of
presenting risk factors.9,10 However, IAP coverage is
incomplete even in the best of settings,11 has no impact
on late onset disease (LOD, occurring from day 7 to 90 of
life), stillbirths and prematurity due to GBS, as well as
a limited impact on disease in pregnant women.10,12
Widespread IAP use might also be an issue in the context
of international efforts to control antimicrobial resistance.
Furthermore, antibiotics might have an effect on the infant
gut flora. Effects of early life events on the neonatal
microbiome have been associated with increased rates of
allergy, asthma and obesity.13–15
Novel Features of a Maternal
Vaccine for GBS
A suitable vaccine against GBS given to pregnant women
could provide effective protection to those forms of inva-
sive disease that cannot be prevented with IAP or where
IAP is not feasible or is incomplete. Furthermore,
a vaccine would be more easily accessible than GBS
culture in all settings and would avoid the need for anti-
microbial administration, avoiding the potential negative
consequences of IAP in the long term.
Maternal immunisation is already a successful tool to
prevent tetanus,16 influenza17 and pertussis18 in young
infants. The placental transfer of maternal antibodies
from mother to infant reduces the window of susceptibility
to infections during the first months of life.19 This same
rationale has been used to investigate new vaccines against
common infections, such as respiratory syncytial virus
(RSV) and GBS.20 A major characteristic of these new
vaccines is that they are being specifically designed for
pregnant women.20
Vaccine Development: Overview of
Current Efforts
During the 2015 World Health Organisation (WHO)
Product Development for Vaccines Advisory Committee
meeting, GBS was identified as a high priority for the
development of a vaccine for maternal immunisation
because of the major public health burden posed by GBS
in low- and middle-income countries (LMIC), and the high
technical feasibility for successful development.21 Recent
estimates suggest that an effective GBS maternal vaccine
(>80% efficacy), with high (90%) global coverage, could
prevent 231,000 infant and maternal GBS cases, 41,000
stillbirths and 66,000 infant deaths annually.3
Evidence suggests that maternal immunisation with
protein-conjugated GBS capsular polysaccharides may
reduce the disease risk in neonates and young infants in
a serotype-specific manner.22–24 In addition, as there are
proteins that can be present in different serotypes, protein-
based vaccines have the potential to provide protection
across the serotype spectrum. These are also under
evaluation.25,26 Table 1 summarizes the development sta-
tus of current vaccine candidates.
Capsular Polysaccharide Conjugate
Vaccines
A number of virulence factors expressed by GBS are
involved in colonisation, adherence, invasion and immune
Table 1 Summary of Different Vaccine Candidates
Vaccine Candidate Preclinical Phase I Phase II Trials in Pregnant Women Phase III
Monovalent and bivalent conjugates (tetanus toxoid/
CRM197-CPS)
x x x x
Trivalent CRM197-CPS conjugates x x x x
Hexavalent CRM197-CPS conjugates x x x x
N-terminal domains of the Rib and AlphaC proteins x x
Pilus proteins x
Other proteins x
Biotinylated CPS conjugates x
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evasion27–29 and these could be used as potential vaccine
candidates. One of the most well-studied virulence factors of
GBS is its unique sialic acid-rich capsular polysaccharide
(CPS) which inhibits complement deposition and protects the
bacteria from opsonophagocytosis by immune cells, thus
contributing to the evasion of host immune defense
mechanisms.30,31 The CPS also enhances biofilm formation,
inhibits the binding of antimicrobial peptides and neutrophil
extracellular traps (NET) as well as disturbing bacterial
adherence to the epithelium and mucus, thus increasing
GBS invasiveness.32–38
GBS expresses 10 types of CPS (Ia, Ib, II–IX) that are
structurally and antigenically different.39–41 Variously
arranged monosaccharides and a sialic acid residue on
the branching terminus of the repeating unit make up the
CPS. According to recent meta-analyses, 97% of invasive
isolates in all geographical regions are caused by five of
the most common serotypes of GBS (Ia, Ib, II, III and V)
with serotype III the most commonly found cause of dis-
ease in infants.5 Serotype IV is an emerging and increasing
cause of invasive disease, especially in non-pregnant
adults, with the potential to become an important cause
of neonatal disease, with some cases already reported.42–45
As polysaccharides are T-cell independent antigens, the
polysaccharide is conjugated to a protein carrier in order to
trigger both a protective and a memory B-cell response.
Earlier vaccines were conjugated to a tetanus toxoid, such
vaccines might have particular value in LMIC where neo-
natal tetanus is still a concern.46,47 However, the main
carrier protein currently used is CRM197, a nontoxic
mutant of diphtheria toxin, which is highly immunogenic.
Studies using either carrier protein demonstrated better
immunogenicity with high levels of antibodies with CPS-
conjugates compared to unconjugated vaccines.48,49
The first clinical trials were conducted with monova-
lent vaccines (Ia, Ib, II, III and V).48–52 However, single
serotypes do not generally produce cross-reactive immu-
nity against other serotypes, thus multivalent vaccines
were developed. A phase I/II clinical trial (registered as
NCT01193920 at the ClinicalTrials.gov database) of
a trivalent (Ia, Ib and III) CRM197 conjugate vaccine in
pregnant women reported higher levels of CPS-specific
antibodies in infants at birth and no safety concerns .53
In 2017, a clinical trial of a GBS polysaccharide conjugate
vaccine targeting serotypes Ia, Ib, II, III and V was started
but, more recently, in view of the increase of disease
caused by serotype IV, this serotype was added to create
an hexavalent vaccine (Ia, Ib, II, III, IV, and V) with the
aim to cover at least 98% of GBS isolates causing neonatal
invasive disease (NCT03170609).5,54 In order to verify the
clinical safety and immunogenicity of this hexavalent vac-
cine, further clinical trials will be required. Currently,
a phase I/II clinical trial (NCT03765073) is being con-
ducted in South Africa to evaluate the safety, tolerability
and immunogenicity of a hexavalent vaccine in healthy
non-pregnant and pregnant women.
It has been shown that opsonophagocytosis is the main
mechanism for the host to clear GBS infection.24 A recent
Phase II study (NCT01446289) demonstrated that mater-
nal antibodies of pregnant women vaccinated with
a trivalent glycoconjugated vaccine composed of CPS Ia,
Ib and III result in opsono-phagocytic killing (OPK) titers
against each GBS serotype. Analysis of cord sera revealed
a strong positive correlation between IgG concentrations
and OPK titers, which is predictive of functional activity
against GBS infection.55
The role of anti-capsular antibodies in preventing GBS
maternal colonisation, as well as ascending infection and
neonatal transmission was recently evaluated in an animal
model.56 Results show that systemic immunisation with
a type III CRM197-glycoconjugate vaccine produces high
levels of IgG that can reduce vaginal acquisition of ser-
otype III during pregnancy.56 Studies in pregnant women
showed the same association with natural immunity.57,58
Further studies will be needed to confirm the same results
in vaccinated women.
Few studies have evaluated the number of doses that
will be required per pregnancy for full immunity. In one
study in healthy, non-pregnant women, no increase in anti-
body levels was shown after a second dose of a trivalent
CRM197-glycoconjugate vaccine administered one month
after the first dose.59 A recent study published in 2019
(NCT02690181) evaluated the safety and immunogenicity
of a second dose of a trivalent (Ia, Ib and III) CRM197
conjugate vaccine in non-pregnant women over a long per-
iod of time (4 to 6 years) after the administration of the first
dose. Antibody levels from previously GBS-vaccinated
women increased ≥200-fold after a second dose. Women
presenting with undetectable antibody levels after first dose
also experienced an increase of anti-GBS concentrations
after a second dose.60 These results suggest that further
doses might be required in subsequent pregnancies.
Serocorrelates of Protection
Although several vaccine candidates are undergoing pre-
clinical and clinical trials, in order to achieve licensure of
Dovepress Carreras-Abad et al
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a vaccine for GBS, phase III clinical trials may be
required. These would need to be very large in order to
demonstrate efficacy in countries able to conduct such
trials.61 As there is a good correlation between immune
response and clinical protection, licensure of a GBS vac-
cine could also be based on antibody measurement, if
a specific antibody response can be correlated with
protection.62–65 A review undertaken in 2019 synthesised
the scientific evidence to define a serocorrelate of protec-
tion against GBS disease based on studies of natural
infection.66 In such a scenario, a phase IV study will be
required post-licensure to assess effectiveness. This is the
same approach used for meningococcal B vaccine licen-
sure in the United Kingdom.67
Assays for Antibody Quantification and
Evaluation
The concentration of antibodies against serotype-specific
CPS antigens can be quantified using standard immuno-
genicity assays (IA). However, there are several limitations
to using current IA as the concentration measurement is
very dependent on how well CPS is immobilized on an
ELISA plate. There are other technical difficulties including
inconsistent binding of immobilized CPS to the solid phase
or a nonspecific serotype-independent binding, of antibo-
dies with lower avidity.49 There has been much debate
about the methods of CPS-binding, for example that used
in pneumococcal assays (poly-L-lycine) or the novel biotin-
streptavidin methods.66,68,69 The biotinylated method has
the advantage of being able to use mass spectroscopy to
determine the exact binding site of the biotin to the CPS,
enabling the monitoring of any potential conformational
changes to the CPS.69 However, whether this affects the
performance of the assay is unknown.
The radio-antigen binding assay (RABA) had been
used successfully to quantify levels of anti-GBS antibody
as it measures antibody in its native state;70 however, as
with most assays, there are several limitations, including
low detection sensitivity, difficulties in obtaining and using
radioisotopes and limited ability to quantify IgG isotopes.
Therefore, it is imperative for techniques quantifying cap-
sular serotype-specific antibodies in serum to be sensitive
as well as serotype-specific.71 Multiplex immunoassays
(MIAs) based on the Luminex technology are very useful
in simultaneously quantifying the concentration of IgG
antibodies against the capsule of multiple GBS serotypes.
A Luminex-based direct immunoassay (dLIA) was
recently developed for pneumococcal CPS.68 The latter
could generate up to 143 test results in a single 96-well
plate using similar principles to an ELISA assay for eval-
uating vaccines in clinical trials. MIAs quantifying IgG
antibodies against the six most frequent GBS capsular
variants (Ia, Ib, II, III, IV and V) would prove to be
extremely useful in the standardisation of the assay used
for GBS vaccine development.
The functionality of antibodies may also have
a significant role in protection against GBS infections.
ELISAs are limited in this aspect as they cannot distin-
guish between antibodies with low avidity and those with
high avidity. Therefore, the opsonophagocytosis killing
assay (OPkA) enables the measurement of antibody
functionality.72 For the validation of the pneumococcal
vaccine, the granulocytic cell line (HL60) was used, mak-
ing the assay more reproducible.73 The assay was also
multiplexed, which proved to be advantageous as it was
less time-consuming and the amount of serum needed for
the assay was reduced.74,75 Although a multiplexed OPkA
for GBS (GBS-MOPA) has been developed for use in
newborns, it only targets serotypes Ia, III and V.76
Therefore, a GBS-OPA targeting all possible vaccine ser-
otypes is necessary for future GBS vaccine development
and evaluation.
Protein Vaccines
Although CPS-conjugate vaccines have been demonstrated
to induce good immunogenicity, there are still several lim-
itations, including potential immune interference with other
types of conjugate vaccines such asHaemophilus influenzae
type b, meningococcal and pneumococcal conjugate
vaccines.77,78 There is also the possibility of serotype repla-
cement and switching post vaccination, as well as an
increase in non-encapsulated GBS strains.79–81 Alternative
vaccine candidates include structurally conserved protein
antigens which can induce a strong immune response
against most GBS strains. In order to develop a vaccine
that can confer broad protection against GBS, several stu-
dies have identified proteins common to all GBS strains.
Members of the Alp family, including AlphaC, Alp1
(Epsilon), Alp2, Alp3 (R28), Alp4 and Rib, are the most
well-known and abundant surface proteins. These proteins
are expressed by different serotypes (Table 2).82–85
Although there have been preclinical vaccine investigations
using AlphaC, Alp3 and Rib proteins, the heterogeneity of
the Alp sequence restricts the use of Alp proteins as poten-
tial vaccine candidates.86,87 Nonetheless, a protein vaccine
Carreras-Abad et al Dovepress
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based on the highly immunogenic N-terminal domains of
AlphaC and Rib (GBS-NN) has been studied in a Phase
I clinical trial (NCT02459262). The participants included
240 healthy women who were immunised with one or two
doses of GBS-NN, generating an elevated level of GBS-NN
specific antibodies by over-30 fold in both groups.82,88 GBS
expresses either one of two-allelic serine-rich repeat 1
(Srr1) and serine rich-repeat 2(Srr2) proteins,89 both of
which can bind to fibrinogen Aα chain through the “dock,
lock and latch” mechanism, thus contributing to the patho-
genesis of GBS meningitis and GBS colonisation of the
vaginal surface.89–91 The antigenic latch domain consisting
of 13 amino acids containing both Srr1 and Srr2, was shown
to play a significant role in GBS pathogenesis. Murine
models have exhibited serotype-independent protection
against GBS infection after being vaccinated with the latch-
peptide vaccine.92 C5a peptidase, which is a GBS virulence
factor, was also considered as a universal protein vaccine or
a carrier for GBS-CPS.93 C5a peptidase encapsulated
within microspheres composed of lactic acid and glycolic
acid co-polymer triggered systemic and mucosal immune
responses in murine models, thus protecting them against
multiple GBS serotypes.94,95 Another type of surface pro-
tein are the pilus proteins, which, in preclinical and human
studies, were found to induce immune responses against
different GBS serotypes.30,96,97
Next Steps, New Perspectives
The most advanced vaccine candidates are hexavalent
vaccines including serotypes Ia, Ib, II, III, IV, and V,
which are now in phase II trials.54 Immunogenicity and
safety of these candidates has been demonstrated in non-
pregnant and, more recently, in pregnant women.22 Protein
vaccines are in phase I trials including human studies in
non-pregnant women.88,92,94-96
Several obstacles exist in moving the most advanced vac-
cines into phase III clinical trials. Given the relatively low
incidence of GBS disease in Europe and the USA, large
numbers of participants would be needed to determine vaccine
efficacy.98 In addition, obstacles exist in determining what
concentration of antibody is required to protect the infant for
the duration of the period at risk (the 3 first months of life) as
there are currently no internationally recognised correlates of
protection with which to interpret individual study results.99
Therefore, a serocorrelate of protection against GBS is needed
to accelerate the licensure of a vaccine. The standardisation of
reagents to measure antibodies against GBS is crucial for the
establishment of serological correlates of protection and for the
development ofGBS vaccines. TheGASTONconsortiumwas
recently set up with this aim.66
On the other hand, efforts to identify common proteins
to all GBS strains have been made in order to find
a vaccine that confers protection against all GBS sero-
types. Recent use of molecular techniques, such as multi-
locus sequence type (MLST) and whole-genome sequen-
cing (WGS), have allowed us to better characterise the
GBS structure, as well as to identify the virulent lineages
such as ST17 hypervirulent strain, strongly associated with
serotype III. As it is important to understand the genetic
lineages that are more likely to cause GBS disease in order
to better define vaccine targets, a global genomic survey of
GBS has been established (the JUNO project).100
Other Areas for Future Research
As mentioned above, it is important to establish rates of
maternal colonisation and GBS disease worldwide, as well
as to understand the relationship between colonisation and
invasive infection, to assist assessments of vaccine efficacy.
Regional serotype distribution is also required, especially from
many LMIC were few data are currently available.
Once a vaccine is licensed, the number and timing of
doses for optimum coverage during pregnancy and the num-
ber of doses required for full protection needs to be deter-
mined. There are other knowledge gaps remaining, including
the placental transfer of vaccine-induced immune responses
in special populations, such as women infected with HIV,
malaria, syphilis and hepatitis B, among others. These infec-
tions, highly prevalent in LMIC, may alter the immune
response to vaccines and impair antibody transfer across
the placenta. A phase II trial using a GBS trivalent vaccine
(Ia, Ib, III) undertaken in Malawi and South Africa among
270 pregnant women with or without HIV infection
(NCT01412801) showed that the immune response to
Table 2 Alp Family Proteins Commonly Expressed in Different
GBS Serotypes
GBS Serotype Alp Family Protein Commonly Expressed
Ia AlphaC, Alp1, Alp2
Ib AlphaC
II AlphaC, Rib
III Rib, Alp2
V Alp2, Alp3
Notes: This table includes only the Alp family proteins that are mostly expressed
by the common serotypes causing infant GBS disease; The uncommon serotypes IV,
VI–IX have not been included as their expression of proteins in the Alp family have
not yet been characterized. Alp1 can also be referred to as Epsilon and Alp3 as R28.
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vaccines and serotype-specific antibody concentrations in
infants at birth were lower in the HIV infected group.101
Maternal immunisation policies require understanding of
the role of these endemic infections in generating immune
responses that ensure adequate protection of infants in these
challenging environments.102,103
Finally, cost-effectiveness evaluation is required. Cost-
effectiveness studies have indicated that the predominant
cost drivers are disease incidence, immunisation coverage
and vaccine efficacy.104 In high income countries, where
GBS disease is well characterized, it has been shown that
a maternal vaccine would be more cost-effective compared
to IAP and doing nothing.105 A population-based eco-
nomic analysis in the USA concluded that vaccinating
80% of pregnant women with a vaccine that prevents
80% of cases among infants born at or after 34 weeks of
gestation would prevent approximately 4100 neonatal
cases annually with a net savings of 131 million USD.105
A study in South Africa also concluded that GBS maternal
vaccination would be very cost-effective by WHO
guidelines.106 This study reported that, assuming that vac-
cine efficacy varies from 50% to 90% with a 75% cover-
age, GBS immunisation alone, without IAP prevention,
would prevent 30–54% of infant GBS cases compared to
doing nothing. In contrast, risk factor based-IAP alone
prevents 10% of infant GBS cases compared to doing
nothing. Furthermore, at a vaccination cost between 10
and 30 USD, and mid-range efficacy, vaccine introduction
costs range from 676 to 2390 USD per disability-adjusted
life-year (DALY) averted, compared to doing nothing.106
A modeling study of different sub-Saharan African coun-
tries showed that maternal GBS immunisation could be
a cost-effective intervention, with cost-effectiveness ratios
similar to other recently introduced vaccines.107 37
African countries were clustered in four different groups
according to their economic and health resources and
public health outcomes. One country of each cluster was
chosen as representative: Guinea-Bissau, Uganda, Nigeria
and Ghana. At equal coverage to that of pregnant women
that attend four or more antenatal visits and with vaccine
efficacy of 70%, maternal vaccination would prevent one-
third of GBS cases in Uganda and Nigeria, 42–43% in
Guinea-Bissau and 55–57% in Ghana. For a vaccine price
of 7 USD per dose, maternal vaccination would cost from
320 to 350 USD per DALY averted in Guinea-Bissau,
Nigeria and Ghana, as well as 573 USD in Uganda. The
vaccine would be less cost-effective in Uganda as neonatal
mortality seems to be lower.107 A recent study by our
group of cost-effectiveness of a potential hexavalent vac-
cine in the Gambia indicated that disease incidence was
the key factor in determining cost-effectiveness in a low
income setting as the cost of doing nothing is very inex-
pensive as infants would classically die at home without
receiving treatment.108 These studies, together with more
epidemiological data in LMIC, might raise the impact
resulting from a vaccine prevention strategy.
Data provided in this review demonstrate that obtaining
a vaccine for pregnant women is a promising strategy to
prevent neonatal and infant GBS disease. Consensus among
public health institutions and sponsors is now a priority to
allow this breakthrough that will help reduce neonatal and
infant mortality, especially in the most vulnerable populations.
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